Clinical trial / 2012
Intravenous ascorbic acid with gemcitabine and erlotinib showed acceptable safety in pancreatic cancer
In a dose-escalation trial of 14 patients with stage IV pancreatic cancer, nine completed an eight-week cycle of thrice-weekly intravenous ascorbic acid alongside gemcitabine and erlotinib. The trial recorded 15 non-serious and eight serious adverse events, all deemed related to disease progression or chemotherapy. RECIST evaluation showed stable disease in seven participants and progressive disease in two, indicating no added toxicity from ascorbic acid.
- Study type
- Phase I dose-escalation trial
- Who was studied
- 14 patients with metastatic stage IV pancreatic cancer
- What was measured
- Safety, adverse events, and disease response
THE PAPER
Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, Pillai MV, Newberg AB, Deshmukh S, Levine M. PLoS One, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.